Menu
Menu
eyeFlow, Inc. is developing a highly effective micro-invasive device for the treatment of the world’s largest cause of irreversible blindness that is:
Potenitally Medication-Free
Surgery using eyeFlow’s device may eliminate the need for high cost medications that come with severe side effects
Simple and Straightforward
eyeFlow takes Micro Invasive Glaucoma Surgery to the next level with the fastest, most accessible procedure to date
Atop A High Growth Market
eyeFlow is the “Best In Class” of Micro Invasive Glaucoma Surgery which dominates the $5.7 billion Glaucoma treatment market
Atop A High Growth Market
eyeFlow is the “Best In Class” of Micro Invasive Glaucoma Surgery which dominates the $5.7 billion Glaucoma treatment market
In early pre-clinical trials, eyeFlow’s Micro Invasive Glaucoma Surgery (MIGS) device has produced very promising results and astonished a World-Renowned Ophthalmologist:
“My early implant experience with eyeflow has been outstanding. I believe its unique design and delivery system is going to appeal to a wide range of physicians and patients as it offers the most consistent mode of implantation.”